November 9, 2017 - 10:00 AM
November 9, 2017 - 11:30 AM
Assessment of Needs
Safe, highly effective, curative direct-acting antiviral (DAA) therapies can eliminate hepatitis C virus (HCV) from the host. This therapeutic revolution raises the prospect of control of the HCV epidemic on a population level. Traditionally, interferon alfa–based therapies were withheld from people who inject drugs because of concerns about precipitating drug use and reinfection. In the DAA era, people who inject drugs have still been systematically denied HCV therapy in most areas of the United States, and new HCV infections have resurged. Rather than denying therapy to people who inject drugs, guidelines suggest prioritizing therapy for these persons, for personal health and public health reasons. This webinar will review the rationale for prioritizing DAA treatment for high-risk persons. The care of people who inject drugs with HCV infection involves more than simply applying antiviral medications, as these persons face special barriers and challenges.
At the conclusion of this webinar, learners will be able to:
- Describe the rationale for prioritizing curative HCV treatments for people who inject drugs
- Cite barriers to the care of people with HCV infection who inject drugs
- Discuss approaches to prevent HCV reinfection and other harmful outcomes among people would inject drugs
Who Should Attend
This webinar is designed for clinical decision makers, such as physicians, nurse practitioners and physician assistants, who have a good understanding of the basics of HCV transmission, testing, and management, and have managed HCV infection in at least 5 patients.
This activity is also relevant for registered nurses, PharmDs, and other health professionals.
Individual registration is required, even if you are viewing as a group, in order to receive CME credit or a certificate of participation.
Registration closes on Wednesday, November 8, 2017, 4:00 PM (PT).
Certificates will be available after the completion of the evaluation and claim form.
For more information or questions, please contact the registration department at registration“at”iasusa.org or 415-544-9400.
Conflicts of Interest
In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.
Continuing Education Credits
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Educational Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Provider # 5-115. This program is approved for 1.5 hours of continuing nursing education.
Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida and the District of Columbia.
Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 1.5 hours (0.15 CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
UAN # 0761-9999-17-302-L01-P
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.
Gilead Sciences, Inc
Frequently Asked Questions
View our list of FAQs about attending a webinar.
Please contact the registration department at registration“at”iasusa.org or 415-544-9400.